The Louisiana State University Health Sciences Center in New Orleans (LSUHSC) MB-CCOP has been providing access to clinical trials to African American and other minority populations in the city and surrounding regions since 1994. In August of 2005, the city was hit by Hurricane Katrina, the worst natural and social disaster to occur in the US since the Civil War. New Orleans experienced the largest mass migration of any US city, and the largest physician migration. LSUHSC, in particular, lost Charity Hospital, its principal enrollment site. It also lost virtually all adult oncologists and support MB-CCOP personnel, and the program's patients were dispersed. A new MB-CCOP leadership implemented an immediate response plan and established a long term reorganization strategy. The immediate response plan enabled us to recruit a team that tracked 90% of the patients by fall 2006, recovered the medical records of these patients, and reestablished follow-up. The long term plan aimed to rebuild the MB-CCOP infrastructure around a private-public partnership with community oncologists. Within two years, these partnerships allowed us to significantly increase our enrollment, maintaining our commitment of providing access to state-of-the-art clinical trials to minority and underserved patients. This paradigm shift from a single site, centrally based MB-CCOP to a community-based, multi-center program also allowed us to begin systematically analyzing the different barriers to minority patient enrollment in the private and public healthcare settings. The goal of our renewal application is to address these barriers and enhance the participation of minorities in MB-CCOP clinical trials. This will be accomplished through three Specific Aims directed at 1) expanding MB-CCOP activities at public hospitals and the state's cancer screening clinics, 2) promoting MB-CCOP activities through private oncology partnerships, and 3) developing targeted community outreach educational programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA063845-11S1
Application #
7916020
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
2009-09-30
Project End
2013-09-29
Budget Start
2009-09-30
Budget End
2013-09-29
Support Year
11
Fiscal Year
2009
Total Cost
$751,419
Indirect Cost
Name
Louisiana State Univ Hsc New Orleans
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
782627814
City
New Orleans
State
LA
Country
United States
Zip Code
70112
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Goldkorn, Amir; Ely, Benjamin; Quinn, David I et al. (2014) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-42
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13
Quinn, David I; Tangen, Catherine M; Hussain, Maha et al. (2013) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 14:893-900
Stiff, Patrick J; Unger, Joseph M; Cook, James R et al. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369:1681-90
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61

Showing the most recent 10 out of 66 publications